A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Trial Parameters
Brief Summary
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
Eligibility Criteria
Inclusion Criteria (abbreviated): 1. Willing and able to provide written informed consent. 2. Aged 18 to 70 years, male or female. 3. Confirmed CD70 positive in tumor tissue by immunohistochemistry (IHC). 4. Only the following subtypes of hematological malignancies with measurable disease will be enrolled: 1. Peripheral T cell lymphoma (including peripheral T cell lymphoma NOS, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, etc.) who have failed ≥1 line of systemic therapy. 2. Cutaneous T cell lymphoma (including mycosis fungoides (MF) or Sézary syndrome (SS) \[stage ≥IIB with disease involving two or more compartments or single-compartment disease with large-cell transformation\]) who have failed ≥2 lines of systemic therapies. 3. Aggressive B cell lymphoma who are refractory or relapsed post ≥2 lines of systemic therapies which contain anti-CD20 antibody and anthracyclines. 4. Indolent B cell lymphoma who are refractory or relapsed post ≥2 lines of systemic thera